Candel Therapeutics Inc. (CADL)

Market Closed

5 Dec, 20:00

NASDAQ (NMS)

5. 33

+0.07

+1.33%

253.64M Market Cap

- P/E Ratio

0% Div Yield

983,471 Volume

-0.91 Eps

$ 5.26

Previous Close

Day Range

5.19 5.43

Year Range

4.25 14.6

Want to track CADL and more in your Portfolio? 🎯

Get Started For Free

Summary

CADL closed Friday higher at $5.33, an increase of 1.33% from Thursday's close, completing a monthly increase of 17.92% or $0.81. Over the past 12 months, CADL stock lost -37.73%.

CADL is not paying dividends to its shareholders.

The last earnings report, released on Nov 13, 2025, exceeded the consensus estimates by 0.17%. On average, the company has surpassed earnings expectations by 0.09%, based on the last three reports.

The stock of the company had never split.

The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

Overview
Earnings
News

CADL Chart

Similar

OBIO

Orchestra BioMed Holdings, Inc.

$ 4.4

-5.98%

ACIU

Acimmune SA

$ 2.8

-2.78%

SNWV

Sanuwave Health Inc.

$ 32.7

-3.55%

NNOX

Nano-X Imaging Ltd.

$ 3.64

-4.96%

TARA

Protara Therapeutics Inc.

$ 5.58

-18.78%

Candel Therapeutics highlights third quarter milestones across cancer immunotherapy pipeline

Candel Therapeutics Inc (NASDAQ:CADL) reported encouraging clinical progress across its cancer immunotherapy pipeline, along with the release of its third quarter 2025 financial results. The company recently presented new Phase 3 subgroup analyses of CAN-2409 in localized prostate cancer showing statistically significant improvement in disease-free survival and updated survival data from its Phase 1b CAN-3110 trial in recurrent high-grade glioma, underscoring the potential of its multimodal immunotherapies.

Proactiveinvestors | 3 weeks ago

Candel Therapeutics secures $130M to fund lead program – ICYMI

Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr. Paul Peter Tak talked with Proactive about the company's recently secured $130 million term loan facility with Trinity Capital.

Proactiveinvestors | 1 month ago

Candel Therapeutics strengthens Research Advisory Board with appointment of immunology expert

Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Dr Bali Pulendran, a leading authority in systems immunology and vaccinology, to its Research Advisory Board. Dr Pulendran is the Violetta L.

Proactiveinvestors | 1 month ago

Candel Therapeutics Inc. (CADL) FAQ

What is the stock price today?

The current price is $5.33.

On which exchange is it traded?

Candel Therapeutics Inc. is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is CADL.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 253.64M.

Has Candel Therapeutics Inc. ever had a stock split?

No, there has never been a stock split.

Candel Therapeutics Inc. Profile

Biotechnology Industry	Healthcare Sector	Paul-Peter Tak FOCIS, CEO	NASDAQ (NMS) Exchange	137404109 CUSIP
US Country	38 Employees	- Last Dividend	- Last Split	27 Jul 2021 IPO Date

Overview

Candel Therapeutics, Inc. is a pioneering clinical-stage biopharmaceutical company rooted in the discovery and development of novel immunotherapies aimed at treating cancer patients. With a focus on leveraging innovative technologies and scientific advances, Candel Therapeutics is committed to achieving breakthroughs in cancer treatment. Since its inception in 2003 under the name Advantagene, Inc., the company has undergone a significant evolution, culminating in a name change to Candel Therapeutics, Inc. in November 2020. Headquartered in Needham, Massachusetts, the organization continues to push the boundaries of cancer therapy with its diverse pipeline of drug candidates and proprietary discovery platforms.

Products and Services

CAN-2409

Currently under Phase II clinical trials for pancreatic cancer, Phase III for prostate cancer, and Phase II for lung cancer, CAN-2409 is a promising candidate in Candel's pipeline, showing potential across multiple cancer types. Additionally, it has completed Phase Ib/II trials for high-grade glioma, emphasizing its versatility in the fight against cancer.

CAN-3110

Aimed at targeting recurrent high-grade glioma, CAN-3110 is undergoing Phase I clinical trials. This exploration signifies Candel's dedication to addressing some of the most challenging and aggressive forms of brain cancer, highlighting their commitment to research and development in oncology.

enLIGHTEN Discovery Platform

An innovative, systematic, iterative HSV-based discovery platform, the enLIGHTEN Discovery Platform is at the cornerstone of Candel Therapeutics' efforts to revolutionize cancer treatment. By leveraging human biology and advanced analytics, it enables the creation of new viral immunotherapies designed to combat solid tumors, embodying Candel's pioneering approach to cancer research and therapy.

Contact Information

Address: 117 Kendrick Street

Phone: 617 916 5445

Website: https://www.candeltx.com

Affiliate Program About Terms Privacy Help Contact Us